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Abstract
Introduction: We have previously demonstrated that endoxifen is the most important tamoxifen metabolite
responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-
alpha (ERα). However, the relevance of ERβ in mediating endoxifen action has yet to be explored. Here, we
characterize the molecular actions of endoxifen in breast cancer cells expressing ERβ and examine its effectiveness
as an anti-estrogenic agent in these cell lines.
Methods: MCF7, Hs578T and U2OS cells were stably transfected with full-length ERβ. ERβ protein stability, dimer
formation with ERα and expression of known ER target genes were characterized following endoxifen exposure.
The ability of various endoxifen concentrations to block estrogen-induced proliferation of MCF7 parental and ERβ-
expressing cells was determined. The global gene expression profiles of these two cell lines was monitored
following estrogen and endoxifen exposure and biological pathway analysis of these data sets was conducted to
identify altered cellular processes.
Results: Our data demonstrate that endoxifen stabilizes ERβ protein, unlike its targeted degradation of ERα, and
induces ERα/ERβ heterodimerization in a concentration dependent manner. Endoxifen is also shown to be a more
potent inhibitor of estrogen target genes when ERβ is expressed. Additionally, low concentrations of endoxifen
observed in tamoxifen treated patients with deficient CYP2D6 activity (20 to 40 nM) markedly inhibit estrogen-
induced cell proliferation rates in the presence of ERβ, whereas much higher endoxifen concentrations are needed
when ERβ is absent. Microarray analyses reveal substantial differences in the global gene expression profiles
induced by endoxifen at low concentrations (40 nM) when comparing MCF7 cells which express ERβ to those that
do not. These profiles implicate pathways related to cell proliferation and apoptosis in mediating endoxifen
effectiveness at these lower concentrations.
Conclusions: Taken together, these data demonstrate that the presence of ERβ enhances the sensitivity of breast
cancer cells to the anti-estrogenic effects of endoxifen likely through the molecular actions of ERα/β heterodimers.
These findings underscore the need to further elucidate the role of ERβ in the biology and treatment of breast
cancer and suggest that the importance of pharmacologic variation in endoxifen concentrations may differ
according to ERβ expression.
Introduction
Each year, nearly 1.3 million women are diagnosed with
breast cancer worldwide and about two-thirds of these
individuals are determined to have hormone sensitive
tumors based on the expression of estrogen receptor-
alpha (ERa). Tamoxifen, a selective estrogen receptor
modulator (SERM), remains an important therapeutic
agent in the treatment of women with endocrine sensi-
tive breast cancer as it is known to effectively inhibit the
proliferation-inducing effects of 17b-estradiol (estrogen)
in ERa positive breast tumor cells.
Like many drugs, tamoxifen is extensively metabolized
in the body by the cytochrome P450 enzyme system
resulting in the production of three primary metabolites;
4-hydroxytamoxifen (4HT), N-desmethyl-tamoxifen
(NDT) and endoxifen [1-3]. Recent reports have
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demonstrated that steady state circulating levels of
tamoxifen, 4HT, and NDT in women receiving the stan-
dard dose of tamoxifen therapy (20 mg/day) are
300 nM, 7 nM, and 700 nM, respectively [4]. However,
plasma endoxifen concentrations are highly variable,
ranging from 5 to 180 nM, due to the activity of the
cytochrome P450 2D6 (CYP2D6) mediated oxidation of
NDT [3]. Prospective studies have demonstrated that
genetic CYP2D6 polymorphisms, and drugs, which
reduce or abrogate CYP2D6 enzyme activity, signifi-
cantly decrease endoxifen plasma concentrations [3-5].
These findings encouraged investigators to examine the
hypothesis that CYP2D6 genotype status, and thus
endoxifen concentrations, would affect clinical outcome
in women treated with tamoxifen for their breast cancer.
Although some controversy remains, the majority of the
reports indicate a relationship between CYP2D6-related
low levels of endoxifen and poor outcomes [6-15]. Past
studies from this laboratory support these clinical find-
ings as we have demonstrated that endoxifen is the
most potent tamoxifen metabolite responsible for inhi-
biting estrogen induced gene expression changes and
proliferation rates in ERa positive breast cancer cells at
clinically relevant concentrations [16]. At this time, the
clinical development of endoxifen is ongoing, with NCI
supported phase I studies of endoxifen hydrochloride
set to commence in early 2011 at both the Mayo Clinic
and NCI.
Tamoxifen and its metabolites are known to function
by blocking the effects of estrogen, a steroid hormone
that binds to, and activates, two main ER isoforms, ERa
and ERb. The role of ERa in breast cancer has been stu-
died extensively for years, and its protein expression
remains the most important biomarker in the treatment
of this disease. However, the potential functions of ERb
in the progression and treatment of breast cancer have
largely remained a mystery. In vitro studies have
revealed that the actions of these two receptors are dras-
tically different at the level of gene expression, both in
response to estrogen and anti-estrogens [17-23]. Numer-
ous reports have demonstrated that exposure of ERa
expressing breast cancer cells to estrogen results in
increased rates of proliferation while more recent stu-
dies have suggested that expression of ERb alone
[21,24,25], or in combination with ERa [26-28], inhibits
cell proliferation following estrogen exposure.
The summation of these in vitro studies suggests that
ERb may function as a tumor suppressor. A number of
clinical studies have revealed that the presence of ERb
protein in breast tumors correlates with improved rates
of recurrence, disease-free survival and overall survival
[29-38] while others indicate little correlation [39-41] or
even worse prognosis [42,43]. Additional studies have
suggested that the expression of ERb in breast tumors
increases the effectiveness of tamoxifen therapy [44-46]
and one report found that 47% of breast tumors classi-
fied as ERa negative express ERb [33]. These observa-
tions highlight the need to further define the relevance
of ERb in breast cancer progression and treatment.
Based on the foregoing, the objective of the present
study was to determine the role of ERb in mediating
endoxifen action in breast cancer cells. The results of
this study demonstrate that ERb enhances the anti-
estrogenic effects of endoxifen in breast cancer cells
likely through the actions of ERa/b heterodimers, and
suggest that the achievement of higher endoxifen con-
centration may not be necessary in patients whose
tumors express ERb and that these same patients may
benefit from tamoxifen therapy regardless of their
CYP2D6 genotype.
Materials and methods
Cell culture, chemicals and reagents
MCF7 cells were generously provided by Dr. Robert
Clarke (Georgetown University) and were cultured in
phenol red-free Dulbecco’s modified Eagle’s medium/
F12 (DMEM/F12) medium containing 10% (v/v) fetal
bovine serum (FBS) and 1% (v/v) antibiotic-antimycotic
(AA) solution in a humidified 37°C incubator with 5%
CO2. MCF7 cells stably expressing ERb were generated
using an S-tagged-Flag-tagged ERb expression construct
(pIRES2-EGFP) developed in our laboratory. Individual
MCF7-ERb clones were isolated following selection with
300 μL/mL G418. Doxycycline inducible Hs578T-ERb,
U2OS-ERb and U2OS-ERa/b cells lines were cultured
as previously described [19-21]. All cell treatments were
conducted in phenol red-free DMEM/F12 medium con-
taining 10% triple charcoal stripped FBS. 17b-estradiol
and doxycyline were purchased from Sigma Aldrich (St.
Louis, MO, USA). PPT (propyl pyrazole triol) and DPN
(diarylpropionitrile) were purchased from Tocris Bios-
ciences Inc. (Baldwin, MO, USA). (Z)-endoxifen was
synthesized by Dr. Abdul Fauq (Mayo Clinic, Jackson-
ville, FL, USA).
Antibodies
The polyclonal ERb specific antibody utilized in this
study was developed by this laboratory. Briefly, a protein
fragment of ERb spanning amino acids 1 to 140 was
cloned into the pGEX-5X-3 vector (Life Technologies,
Carlsbad, CA, USA) and expressed in DH5a bacterial
cells. Purified ERb protein was immunized in rabbits by
Cocalico Biologicals Inc (Reamstown, PA, USA). ERb
specific antibodies were purified from serum using an
affinity purification column containing the ERb protein
fragment. We have extensively characterized this anti-
body through Western blotting, immunoprecipitation,
immunohistochemistry and immunoflourescence using
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multiple cell model systems which express either no
ERs, ERa alone, ERb alone or a combination of ERa
and ERb, to ensure its specificity for the b isoform.
These data have revealed that this antibody is highly
sensitive for the detection of ERb and exhibits no cross-
reaction with ERa or other proteins (data not shown).
ERa (H-20) antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Flag (M2) and
a-Tubulin (DM 1A) antibodies were purchased from
Sigma Aldrich.
Western blotting
All cell lysates were harvested using NETN buffer
(150 mM NaCl, 1 mM EDTA, 20 mM Tris (pH 8.0),
0.5% Nonidet P-40) and insoluble material was pelleted.
Protein concentrations were determined using Bradford
Reagent and equal amounts of cell lysate were separated
by SDS-PAGE. Proteins were transferred to PVDF mem-
branes, probed with primary and secondary antibodies
and visualized using enhanced chemiluminescence
(Amersham Biosciences, Piscataway, NJ, USA).
Immunofluorescent staining analysis
MCF7-ERb cells were plated on cover slides at approxi-
mately 50% confluence and fixed with cold methanol for
one hour followed by permeabilization with 0.1% Triton
X-100 for five minutes on ice. Slides were pre-incubated
in 5% goat serum for one hour followed by exposure to
Flag antibody for another hour. Slides were washed
three times with 1× PBS and subsequently incubated
with Rhodamine-labeled anti-mouse secondary antibody
(Sigma-Aldrich) for 30 minutes at room temperature.
Nuclei were simultaneously stained with DAPI (Sigma-
Aldrich). Immunofluorescent detection was conducted
using a Zeiss Laser Scanning Microscope 510 (Carl
Zeiss, Jena, Germany)
Luciferase assays
MCF7-ERb cells were plated in 12-well tissue culture
plates at approximately 70% confluence and subse-
quently transfected in triplicate with 250 ng per well of
the ERE-TK-luciferase reporter construct using Fugene
6 (Roche Applied Science, Indianapolis, IN, USA). Fol-
lowing transfection, cells were treated as indicated for
24 h. Cells were lysed in 1× Passive Lysis Buffer (Pro-
mega, Madison, WI, USA) and equal amounts of extract
were assayed for luciferase activity.
Co-Immunoprecipitation assays
MCF7-ERb or U2OS-ERa/b cells were plated at a density
of approximately 50% in 100 mm tissue culture plates.
U2OS cells were treated with doxycycline as previously
described to induce expression of ERa and ERb [20] and
subsequently exposed to indicated concentrations of
endoxifen. Following 24 hours of incubation, cells were
washed twice with PBS and lysed in NETN buffer. Equal
amounts of cell lysates were immunoprecipitated at 4°C
overnight using 1 μg of either Flag or ERb antibody. Pro-
tein complexes were purified using protein G beads,
separated by SDS-PAGE, transferred to PVDF mem-
branes and blocked in 5% milk overnight. Western blot-
ting was performed using indicated antibodies as
described above.
Real-time reverse transcriptase polymerase chain reaction
MCF7 and MCF7-ERb cells were plated in 12-well tis-
sue-culture plates and treated in triplicate as indicated
for 24 hours. Total RNA was isolated using Trizol
reagent (Invitrogen) and 500 ng was reverse transcribed
using the iScript™ cDNA Synthesis Kit (Bio-Rad). Real-
time PCR was performed in triplicate using a Bio-Rad
iCycler (Hercules, CA, USA) and a PerfeCTa™ SYBR
Green Fast Mix™ for iQ real-time PCR kit (Quanta
Biosciences, Gaithersburg, MD, USA) as specified by the
manufacturer. Quantitation of the PCR results were cal-
culated based on the threshold cycle (Ct) and were nor-
malized using TATA Binding Protein as a control. All
PCR primers were designed using Primer3 software [47]
and were purchased from Integrated DNA Technologies
(Coralville, IA, USA). Primer sequences are provided in
Additional file 1.
Cell proliferation assays
MCF7 and MCF7-ERb cells were grown in 10% triple
charcoal-stripped serum-containing medium for three
days and subsequently plated at a density of 2,000 cells
per well in 96-well tissue culture plates. Cells were trea-
ted with vehicle, 1 nM estrogen or 1 nM estrogen plus
increasing concentrations of endoxifen (20 to 1,000 nM)
for eight days. Culture medium and treatments were
replaced every other day. Proliferation rates were deter-
mined using a CellTiter-Glo Luminescent Cell Viability
kit (Promega).
Illumina microarray analysis
Changes in the gene expression profiles of MCF7 and
MCF7-ERb cells elicited by either 1 nM estrogen alone
or estrogen plus 40 nM endoxifen were determined
using the Illumina HumanHT-12 expression BeadChip
platform to screen more than 27,000 annotated
genes represented by 48,804 probes by Mayo Clinic’s
Advanced Genomics Technology Center (Rochester,
MN, USA). Data were processed using BeadStudio Ver-
sion 3.1 and normalized using the fastlo function [48]
implemented in the statistical package R. Data were fil-
tered to exclude probes (referred to as genes through-
out) whose expression was at or below background
levels as determined by detection P-values (≥0.05).
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Pair-wise comparisons were made to identify differen-
tially expressed genes using Linear Models for Microar-
ray Data (LIMMA). Genes were determined to be
significantly regulated if their differential P-value was
<0.05 between groups. Fold changes were calculated by
raising 2 to the power of mean difference (log 2 scale)
between the treatment groups and controls. The nor-
malized and raw microarray data presented here are
available in the Gene Expression Omnibus [49] under
the accession number: [GEO:GSE27375].
Biological pathway analysis
Genes determined to be significantly regulated by the
addition of 40 nM endoxifen relative to estrogen alone
in both parental and ERb expressing MCF7 cells were
further analyzed using MetaCore software to identify
differences in biological pathways altered between the
two cell lines. Genes with differential expression
P-values < 0.05 from each comparison were used as
focus genes and a hypergeometric test was applied to
each of over 600 canonical pathways. Enriched pathways
with P-values < 0.05 were suggested to be significantly
regulated by the addition of 40 nM endoxifen within
each cell line. Adjustment for multiple comparisons was
conducted using a false discovery rate of 0.25.
Results
Development and characterization of MCF7-ERb cell lines
In order to determine the effects of ERb expression on
the actions of endoxifen in breast cancer, we first devel-
oped MCF7 cell lines stably expressing this receptor.
MCF7 cells were chosen for this study since they are
the most well characterized ERa positive breast cancer
cell line with regard to estrogen regulated gene expres-
sion and proliferation. As shown in Additional file 2, the
parental MCF7 cell line used throughout this study was
confirmed to be ERb negative by both real-time PCR
and Western blotting and these data are shown relative
to the expression of ERb mRNA and protein in one of
our over-expressing cell lines. Multiple MCF7-ERb clo-
nal cell lines were developed by expressing S and Flag-
tagged full-length ERb followed by selection with G418.
All cell lines were screened for ERb protein expression
by Western blotting and three representative lines are
shown in Figure 1A relative to parental cells. While all
of the data presented in Figures 1, 2, 3, 4 were con-
firmed in multiple MCF7-ERb clones, the data collected
from clone number 3 were chosen for representation in
these figures due to its robust expression of ERb. Immu-
nofluorescent staining using a flag antibody was utilized
to verify ERb positivity and cellular localization. The
results demonstrate that ERb is expressed and localized
in the nucleus of MCF7-ERb cells (Figure 1B). ERb
functionality was investigated using an estrogen
response element (ERE) transcriptional assay involving
an ERE-TK-luciferase reporter construct. The construct
was transfected into parental and ERb expressing MCF7
cells followed by treatment with either estrogen, the
ERa specific agonist PPT or the ERb specific agonist
DPN. As shown in Figure 1C, estrogen significantly
induced ERE activity in both MCF7 parental and ERb
expressing cells. Interestingly, estrogen induction of the
ERE was significantly lower in ERb expressing cells pos-
sibly due to the reported inhibitory actions of ERb on
ERa transcriptional activity. The ERb specific agonist,
DPN, resulted in significant activation of the ERE repor-
ter construct in cells expressing ERb (Figure 1C). ERE
activation in parental MCF7 cells by 10-8 M DPN is
explained by its non-specific interactions with ERa at
Figure 1 Characterization of MCF7-ERb cell lines. (A) Western
blot (WB) analysis demonstrating expression of ERb in three
independent clonal MCF7 cell lines. (B) Immunoflourescence
depicting nuclear localization of ERb protein in stably expressing
MCF7 cell lines. (C) Luciferase assays demonstrating transcriptional
activation of a transiently transfected ERE by either ERa or ERb in
parental and MCF7-ERb cell lines using estrogen, the ERa specific
agonist PPT or the ERb specific agonist DPN. * denotes significance
at the P < 0.05 level (ANOVA) compared with vehicle controls while
# denotes significance for a given treatment between the two cell
lines.
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high concentrations [50]. As expected, all concentrations
of the ERa specific ligand, PPT, resulted in identical
ERE activation regardless of ERb expression (Figure 1C).
These data demonstrate that our newly developed
MCF7-ERb cell lines express intact and functional ERb
protein.
ERb protein levels are stabilized by endoxifen
Since we have previously demonstrated that endoxifen
exposure results in rapid turnover of ERa protein in
multiple cell types through proteasomal degradation
[16], it was of interest to determine the effects of endox-
ifen on ERb protein levels. Unlike that of ERa, endoxi-
fen exposure resulted in stabilization of ERb protein in
MCF7-ERb cells in a concentration dependent manner
(Figure 2A). These results were confirmed in Hs578T
breast cancer cells and U2OS osteosarcoma cells stably
expressing ERb (Figure 2B, C).
Endoxifen induces ERa/b heterodimer formation
Given that ERb protein levels are stabilized by endoxifen
and that ERb interacts with ERa, we next sought to
determine if endoxifen exposure resulted in ERa/b het-
erodimer formation. Immunoprecipitation assays
demonstrate that endoxifen induces ERa/b heterodimer
formation in MCF7-ERb cells which results in the stabi-
lization and accumulation of ERa protein levels (Figure
3A). These studies were conducted in U2OS cells stably
expressing both ER isoforms and similar results were
observed (Figure 3B). The results of these studies
demonstrate that exposure of cells which express both
ER isoforms to endoxifen results in stabilization and
accumulation of both ERa and ERb protein likely due to
its induction of heterodimer formation. It is speculated
that ERa and ERb homodimer formation likely occurs
to some degree as well.
Endoxifen’s ability to inhibit estrogen induced gene
expression and proliferation is enhanced by ERb
Our laboratory previously characterized the inhibition of
estrogen induced gene expression and proliferation by
endoxifen in MCF7 cells [16]. In order to determine the
effects of ERb expression on the anti-estrogenic actions
of endoxifen, we next compared the ability of endoxifen
to inhibit estrogen induction of known ERa target genes
Figure 2 Stabilization of ERb protein levels by endoxifen .
Western blot (WB) analysis of ERb protein levels in MCF7-ERb (A),
Hs578T-ERb (B) and U2OS-ERb (C) cells treated with indicated
concentrations of endoxifen or vehicle for 24 hours. Tubulin levels
are shown as protein loading controls.
Figure 3 Endoxifen induces ERa/b heterodimer formation.
MCF7-ERb (A) or U2OS-ERa/b (B) cells were treated with indicated
concentrations of endoxifen or vehicle for 24 hours. Equal amounts
of cell lysates were immunoprecipitated with an ERb specific
antibody. Immunoprecipitated protein (IP) complexes were
separated by SDS-PAGE and Western blotting (WB) was performed
using an ERa specific antibody. Non-immunoprecipitated ERa and
ERb protein levels were also determined by Western blotting in
whole cell extracts (WCE) following endoxifen treatment. Tubulin
levels are shown as protein loading controls.
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in parental and ERb expressing MCF7 cells. The expres-
sion levels of cyclinD1, PS2, progesterone receptor and
amphiregulin were monitored in both cell lines by real-
time PCR following treatment with estrogen alone or
estrogen plus increasing concentrations of endoxifen. In
contrast to the ERE data presented in Figure 1, estrogen
treatment further stimulated the expression of three of
the four genes (PS2, PGR and AREG) in ERb expressing
cells relative to the parental cell line (Figure 4A-D).
Interestingly, low concentrations of endoxifen (20 nM)
significantly inhibited the estrogen induction of three of
the four genes (CCND1, PS2 and PGR) only in ERb
expressing cells while higher endoxifen concentrations
(100 to 1,000 nM) resulted in similar patterns of gene
expression between the two cell lines (Figure 4A-D).
These data suggest that expression of ERb, in ERa posi-
tive breast cancer cells, enhances the anti-estrogenic
properties of endoxifen.
To confirm these data, and to determine if expression
of ERb enhances the ability of endoxifen to suppress
estrogen induced cell growth, proliferation assays were
performed. Two independent ERb expressing cell lines
are shown for these studies to ensure that the results
are due to expression of ERb and not clonal variation.
Figure 4 Repression of known ER target genes by endoxifen is enhanced in ERb expressing cells. Parental MCF7 and MCF7-ERb cells
were treated as indicated for 24 hours. Real-time RT-PCR analysis was performed to detect expression levels of (A) cyclin D1 (CCND1), (B) PS2,
(C) progesterone receptor (PR) and (D) amphiregulin (AREG). * denotes significance at the P < 0.05 level (ANOVA) compared to vehicle,
# compared to estrogen treatment and δ for a given treatment between the two cell lines.
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Induction of cell proliferation following estrogen treat-
ment was identical between parental and ERb expressing
MCF7 cells (Figure 5). Similar to the gene expression
data presented in Figure 4, low concentrations of endox-
ifen (20 to 40 nM) significantly inhibited estrogen
induced growth of MCF7-ERb cells but not parental
MCF7 cells (Figure 5). In fact, 100 to 1,000 nM concen-
trations of endoxifen were required to completely block
estrogen induced growth of parental MCF7 cells while
20 to 40 nM endoxifen concentrations were essentially
as effective in ERb positive cells (Figure 5). These stu-
dies confirm that ERb expression sensitizes breast can-
cer cells to the anti-estrogenic actions of endoxifen.
ERb expression results in unique gene expression
patterns following estrogen and endoxifen exposure
In an effort to determine the mechanisms by which low
concentrations of endoxifen effectively block estrogen
induced growth of ERb expressing cells, but not parental
MCF7 cells, the global gene expression profiles were
examined in these two cell lines following treatment
with estrogen alone or estrogen plus 40 nM endoxifen.
The 40 nM endoxifen concentration was chosen since it
resulted in the largest differences in proliferation rates
between parental and MCF7-ERb cells. Microarray ana-
lysis revealed that estrogen treatment significantly
altered the expression of 461 genes in parental MCF7
cells using a fold change cutoff of 1.5 (Figure 6A). Of
these genes, 211 exhibited increased expression while
251 exhibited decreased expression. Nearly 2.5 times as
many genes were determined to be significantly regu-
lated in the MCF7-ERb cell line using the same statisti-
cal and fold change cutoff parameters. Specifically, 1,137
genes were differentially expressed following estrogen
treatment of which 604 were increased and 535 were
decreased (Figure 6A). Comparison of these two data
sets revealed that 381 (31%) were commonly regulated
between the two cell lines, while only 80 (7%) were
unique to the parental cell line and 756 (62%) were
unique to the ERb line (Figure 6A). A list of these genes
and their detected fold changes is provided in
Additional file 3. Two genes exhibiting increased expres-
sion and two genes exhibiting decreased expression in
response to estrogen treatment were randomly selected
for each cell line and confirmed by real-time PCR. The
relative expression levels for these genes as determined
by both microarray and real-time PCR are shown in
Figure 6B.
We next compared the microarray results of parental
and MCF7-ERb expressing cells treated with estrogen
plus 40 nM endoxifen to estrogen treatment alone.
Using the same selection criteria as above, significantly
fewer genes were determined to be regulated by this
dose of endoxifen. In the parental cell line, the expres-
sion levels of 75 genes were altered by at least 1.5-fold
by the addition of endoxifen of which 44 were increased
and 31 were decreased (Figure 6C). Similar results were
observed in the MCF7-ERb cell line in that a total of 78
genes were differentially regulated in response to endox-
ifen with 37 exhibiting increased expression and
Figure 5 Low concentrations of endoxifen inhibit estrogen induced proliferation of MCF7-ERb cells. Parental and MCF7-ERb cells (cell
lines #1 and #3) were treated as indicated for eight days and cell proliferation rates were analyzed. Graphs depict fold change from vehicle
treated cells. * denotes significance at the P < 0.05 level (ANOVA) compared to vehicle controls, # compared to estrogen treated cells and δ for
a given treatment between the two cell lines.
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41 exhibiting decreased expression (Figure 6C). Compar-
ison of these two data sets indicated that 46 genes (43%)
were commonly regulated in both cell lines while 29
(27%) were unique to the parental cells and 32 (30%)
were unique to the ERb expressing cells (Figure 6C).
A list of these genes and their detected fold changes is
provided in Additional file 4. As above, two genes exhi-
biting increased expression and two genes exhibiting
decreased expression in response to endoxifen treatment
were randomly selected for each cell line and confirmed
by real-time PCR. The relative expression levels of these
genes as determined by both microarray and real-time
Figure 6 Microarray analysis of estrogen and estrogen plus endoxifen treatment in parental and MCF7-ERb cells. (A and C) Venn
diagrams indicating the number of genes whose expression levels were significantly altered by at least 1.5-fold in response to 24-hour
treatments of 1 nM estrogen in MCF7 or MCF7-ERb cells (A) or 1 nM estrogen + 40 nM endoxifen relative to estrogen treatment alone (C). (B
and D) Real-time PCR confirmation of selected genes whose expression levels were either increased or decreased by the addition of estrogen in
MCF7 or MCF7-ERb cells (B) or 1 nM estrogen + 40 nM endoxifen relative to estrogen treatment alone (D). The fold changes of each gene as
detected by microarray analysis are shown for comparison purposes and all data have been normalized to vehicle controls (dotted line).
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PCR following estrogen treatment alone and estrogen
plus endoxifen are shown in Figure 6D.
As with the proliferation data, to ensure that the
detected gene expression differences in response to
estrogen and endoxifen were truly due to the presence
of ERb and not a result of clonal variation, the confir-
mation of gene expression studies were also carried out
in a second ERb cell line (#1). These results revealed the
same trends in gene expression elicited in response to
both estrogen and endoxifen (Figure 7A, B) and suggest
that these differences are in fact a result of ERb expres-
sion and not due to clonal variation between cell lines.
Pathway analysis identifies specific biological processes
that are uniquely regulated by endoxifen in MCF7-ERb
cells
Pathway analysis was performed on the gene lists gener-
ated from both the parental and MCF7-ERb cells treated
with estrogen plus 40 nM endoxifen relative to estrogen
alone. For this analysis, all genes whose expression levels
were significantly altered (P < 0.05) by the addition of
endoxifen and whose fold changes were >2 standard
deviations away from all genes kept in the analysis
(approximately 1.2-fold) were utilized. This analysis
identified 13 pathways in the parental cell line and 12
pathways in the MCF7-ERb cell line which had signifi-
cant enrichment of genes based on a P < 0.05. While
none of these pathways passed a false discovery rate
threshold of 0.25 after adjusting for multiple compari-
sons likely due to relatively small numbers of genes, it is
interesting to note that biological pathways involving
ERa cell cycle regulation and cell migration were only
affected by endoxifen in breast cancer cells expressing
ERb (Table 1). As with the gene expression data, many
of the identified pathways were unique to either the par-
ental or ERb expressing cell lines (identified by an aster-
isk) lending further support to the differential effects of
endoxifen as a result of ER isoform specific expression
(Table 1).
Discussion
Endocrine sensitive breast cancer
The large majority of breast cancer patients display
tumors that are estrogen dependent based on the
expression of ERa. Deprivation of estrogen signaling,
most commonly through the use of tamoxifen in the
adjuvant setting, typically results in tumor regression.
However, the use of ERa alone as an indicator of
responsiveness to anti-estrogens is far from perfect as
about one-half of ERa positive tumors do not respond
to tamoxifen therapy and about 10% of ERa negative
tumors do respond. These studies demonstrate that
other estrogen and anti-estrogen receptors and/or sig-
naling pathways may be involved in mediating the
responsiveness of endocrine sensitive tumors to hormo-
nal agents. Following the discovery of ERb, investigators
have sought to uncover the role that this protein may
play in mediating breast cancer progression and treat-
ment. Here, we demonstrate that expression of ERb in
ERa positive MCF7 cells significantly enhances the anti-
estrogenic effects of endoxifen. This study provides evi-
dence that endoxifen stabilizes ERb protein levels and
induces ERa/b heterodimer formation which results in
differential gene expression patterns. Perhaps most
importantly, our studies reveal that even low concentra-
tions of endoxifen, mimicking that of poor and inter-
mediate CYP2D6 metabolizers, results in repression of
estrogen induced breast cancer proliferation in cells
expressing ERb, but not in those that express only ERa.
Role of ERb in breast cancer
ERb is known to be expressed in normal breast epithe-
lial cells and several studies have demonstrated that ERb
expression levels are suppressed in many breast cancers
[51-54]. However, re-expression of ERb in ER negative
breast cancer cells has been shown to reduce both basal
and estrogen induced proliferation rates [21,24,25].
Expression of ERb in ERa positive breast cancer cells
also results in suppression of proliferation following
estrogen exposure [26-28]. Furthermore, ERb expression
has been shown to increase the effectiveness of high
concentrations of SERMs such as 4HT, raloxifen and
fulvestrant [28,55] in vitro. While the latter studies did
not analyze endoxifen, nor did they utilize clinically rele-
vant concentrations of 4HT (plasma concentrations are
less than 10 nM in patients receiving 20 mg/day), they
do further implicate a role for ERb in mediating anti-
estrogenic activities.
It is possible that the increased effectiveness of endox-
ifen in ERb expressing MCF7 cells is related to the
molecular actions of ERa/b heterodimers since we
demonstrate that heterodimer formation is induced in a
concentration dependent manner following endoxifen
exposure. Indeed, the global gene expression changes
induced by estrogen and anti-estrogens are known to be
different in cells expressing both estrogen receptors rela-
tive to cells expressing only ERa or ERb [20,21,56]. The
results of the present study also demonstrate that both
estrogen and endoxifen regulate unique subsets of genes
in MCF7 cells expressing both receptors relative to cells
expressing ERa alone. Biological pathway analysis of
endoxifen regulated genes revealed that the majority of
altered pathways are unique to either the parental or
ERb expressing cell lines. Pathways involving ERa
mediated cell cycle regulation and cell migration were
only affected in the presence of ERb suggesting that the
increased effectiveness of endoxifen may be through the
inhibition of ERa activity by ERb.
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Figure 7 Confirmation of microarray data in a second ERb expressing MCF7 cell line. (A and B) Real-time PCR confirmations were also
carried out in a second ERb cell line (#1) to ensure that the detected gene expression changes were due to the presence of ERb and were not
a result of potential clonal variation between cell lines. Relative fold changes of genes determined to be regulated by 1 nM estrogen alone (A)
or by 1 nM estrogen + 40 nM endoxifen relative to estrogen treatment alone (B) are shown following normalization to vehicle controls (dotted
line). The same trends in gene expression were detected in response to both estrogen and endoxifen in this second ERb expressing cell line.
Table 1 Biological pathways regulated by estrogen plus 40 nM endoxifen relative to estrogen treatment alone
MCF7 Parental Cells
Pathway # Pathway Name P-Value # Genes
1* Immune response_Antiviral actions of Interferons 0.0008 6/20
2* Immune response_IFN gamma signaling pathway 0.0177 6/36
3 Regulation of lipid metabolism_Regulation of fatty acid synthase activity 0.0182 3/10
4 Neurodisease_Parkin disorder under Parkinson disease 0.0191 4/18
5* Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 1 0.0195 2/4
6* Cholesterol Biosynthesis 0.0276 4/20
7* Niacin-HDL metabolism 0.0305 3/12
8* Cytoskeleton remodeling_Thyroliberin in cytoskeleton remodeling 0.0305 3/12
9 CFTR-dependent regulation of ion channels in Airway Epithelium 0.0326 4/21
10 Immune response_IL-27 signaling pathway 0.0380 3/13
11* Development_A1 receptor signaling 0.0440 4/23
12* Neurophysiological process_PGE2-induced pain processing 0.0450 2/6
13* Immune response_Th1 and Th2 cell differentiation 0.0463 3/14
MCF7-ERb Cells
1* wtCFTR and deltaF508 traffic/Membrane expression (norm and CF) 0.0026 5/16
2 Regulation of lipid metabolism_Regulation of fatty acid synthase activity 0.0026 4/10
3 Immune response_IL-27 signaling pathway 0.0077 4/13
4* Blood coagulation_Blood coagulation 0.0132 4/15
5* Cell cycle_ERa regulation of G1/S transition 0.0167 5/24
6* Globo-(isoglobo) series GSL Metabolism 0.0228 3/10
7 Neurodisease_Parkin disorder under Parkinson disease 0.0254 4/18
8* ERa action on cytoskeleton remodeling and cell migration 0.0299 3/11
9* Transcription_Ligand-Dependent Transcription of Retinoid-Target genes 0.0306 4/19
10* ENaC regulation in airways (normal and CF) 0.0364 4/20
11 CFTR-dependent regulation of ion channels in Airway Epithelium 0.0427 4/21
12* wtCFTR and delta508-CFTR traffic/Generic schema (norm and CF) 0.0463 5/31
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Compounds which induce ER heterodimer formation as
therapeutic drugs
The ability of specific compounds to induce ER hetero-
dimer formation is of significant importance since these
two receptors are often expressed in the same cells of
many different tissues, including breast tumors, and
since different dimer pairs have distinct genomic targets
[57]. Of particular interest is the observation that genis-
tein, a compound originally thought to contribute to
decreased breast cancer risk, specifically induces ERa
homodimerization and transcriptional activity [58]. This
observation correlates well with more recent studies
demonstrating that genistein is not effective in the pre-
vention of breast cancer [59,60]. Conversely, liquiriti-
genin is a highly selective ERb agonist which does not
stimulate ERa positive tumor formation [61] or ERa
homodimerization [58] suggesting that it may serve as a
suppressor of proliferation in ERb expressing cells. The
summation of these studies indicates that the identifica-
tion of compounds which can specifically induce and/or
activate ERa/b heterodimers or ERb homodimers may
have therapeutic potential. Endoxifen may serve as such
a compound since it stabilizes ERb protein levels and
induces heterodimer formation in cells expressing both
ER isoforms while simultaneously degrading ERa pro-
tein in ERb negative cells [16].
Impact of ERb positivity and increased endoxifen
effectiveness
The identification of increased endoxifen effectiveness as
an anti-estrogenic agent in the setting of ERb is of sig-
nificant clinical importance due to the fact that ERb
expression is reported to exist in approximately 75% of
invasive breast cancers [33,36,37,42,62-64] and in a sub-
set of tumors which are ERa negative [41,45,65]. The
majority of reports suggest that the presence of ERb in
breast tumors correlates with improved rates of recur-
rence, disease-free survival and overall survival [29-38];
however, others indicate little correlation [39-41]. A few
recent clinical studies have revealed that ERb increases
the effectiveness of tamoxifen therapy for breast cancer
[44-46]. Given that endoxifen is being developed for the
treatment of ER positive breast cancer, future studies
should evaluate the association between ERb expression
and the activity of endoxifen in human breast tumors.
Conclusions
The present data indicate that ERb enhances the anti-
estrogenic actions of endoxifen in breast cancer cells.
These data correlate well with the clinical studies
demonstrating increased benefit from tamoxifen therapy
in those patients whose tumors are ERb positive and
suggest that this benefit may be through the actions of
endoxifen. The ability of low endoxifen concentrations
to significantly inhibit estrogen induced gene expression
and proliferation in ERb expressing breast cancer cells
also suggests that benefits from tamoxifen therapy may
still be observed in patients characterized as poor meta-
bolizers based on CYP2D6 genotype if their tumors are
ERb positive. Finally, these studies highlight the need to
further investigate the role of ERb in breast cancer, both
as a prognostic and predictive factor, and lend addi-
tional support to the development of endoxifen as a
novel therapeutic for the treatment of endocrine sensi-
tive breast tumors.
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